Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy

Genes and Immunity

Volumn 14, Issue 5, 2013, Pages 317-324

  Lopez Rodriguez R ^a   Hernandez Bartolome A ^a   Borque, M J ^b   Rodriguez Munoz Y ^a   Martin Vilchez S ^a   Trapero Marugan M ^a   Garcia Buey L ^a   Munoz De Rueda P ^c   Rodrigo, L ^d   Vidal Castineira J R ^d   Salmeron J ^c   Moreno Otero, R ^a   Sanz Cameno, P ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Chronic hepatitis C; HDAC; IL 28B; Pegylated interferon; Ribavirin; Sustained virological response

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; UNCLASSIFIED DRUG;

ALLELE; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; GENE EXPRESSION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN PROCESSING; RECEIVER OPERATING CHARACTERISTIC; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 84880918097     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2013.24     Document Type: Article

References (34)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567. (Pubitemid 41196755)
2. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 257-264.
3. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-432. (Pubitemid 36250066)
4. de Rueda PM, Lopez-Nevot MA, Saenz-Lopez P, Casado J, Martin-Casares A, Palomares P et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated Interferon and ribavirin. Am J Gastroenterol 2011; 106: 1246-1254.
5. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
6. Lopez-Rodriguez R, Trapero-Marugan M, Borque MJ, Roman M, Hernandez-Bartolome A, Rodriguez-Munoz Y et al. Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. Clin Pharmacol Ther 2011; 90: 712-721.
7. Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 2011; 8: e1001092.
8. Zaidi SK, Young DW, Montecino M, van Wijnen AJ, Stein JL, Lian JB et al. Bookmarking the genome: maintenance of epigenetic information. J Biol Chem 2011; 286: 18355-18361.
9. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10: 32-42.
10. Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol 2011; 2011: 371832.
11. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-840.
12. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009; 41: 185-198.
13. Chang HM, Paulson M, Holko M, Rice CM, Williams BR, Marie I et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 2004; 101: 9578-9583. (Pubitemid 38869278)
14. Icardi L, Lievens S, Mori R, Piessevaux J, De Cauwer L, De Bosscher K et al. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2. FASEB J 2012; 26: 240-249.
15. Kadota S, Nagata K. Pp32, an INHAT component, is a transcription machinery recruiter for maximal induction of IFN-stimulated genes. J Cell Sci 2011; 124(Part 6): 892-899.
16. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012; 56: 1343-1350.
17. Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R et al. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 2011; 459: 129-139.
18. Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2007; 72: 69-74. (Pubitemid 350249132)
19. Yang Z, Zhou L, Wu LM, Xie HY, Zhang F, Zheng SS. Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy. Clin Chem Lab Med 2010; 48: 1785-1791.
20. Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2011; 31: 537-551.
21. Witthoeft T, Hueppe D, John C, Goelz J, Heyne R, Moeller B et al. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat 2010; 17: 459-468.
22. Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 2007; 150: 829-831. (Pubitemid 46536629)
23. Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA 2003; 100: 14742-14747. (Pubitemid 37517961)
24. Nusinzon I, Horvath CM. Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol Cell Biol 2006; 26: 3106-3113.
25. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
26. Kramer OH, Heinzel T. Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol 2011; 315: 40-48.
27. Kramer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, Guhrs KH et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev 2009; 23: 223-235.
28. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW. Liverspecific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J 2008; 27: 1017-1028. (Pubitemid 351508160)
29. Holden M, Deng S, Wojnowski L, Kulle B. GSEA-SNP: applying gene set enrichment analysis to SNP data from genome-wide association studies. Bioinformatics 2008; 24: 2784-2785. (Pubitemid 352722627)
30. Lindh M, Lagging M, Farkkila M, Langeland N, Morch K, Nilsson S et al. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203: 1748-1752.
31. Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, Steindl-Munda P et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011; 54: 866-871.
32. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther 2012; 36: 91-103.
33. Schreiber J, Moreno C, Garcia BG, Louvet A, Trepo E, Henrion J et al. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and-3 patients. Aliment Pharmacol Ther 2012; 36: 353-362.
34. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22: 1928-1929. (Pubitemid 44283043)